Literature DB >> 29110839

Challenging a dogma; AJCC 8th staging system is not sufficient to predict outcomes of patients with malignant pleural mesothelioma.

Omar Abdel-Rahman1.   

Abstract

BACKGROUND: The 8th edition of malignant pleural mesothelioma (MPM) American Joint Committee on Cancer (AJCC) staging system has been published. The current analysis aims to evaluate its performance in a population-based setting among patients recorded within the surveillance, epidemiology and end results (SEER) database.
METHODS: SEER database (2004-2013) has been accessed through SEER*Stat program and AJCC 8th edition stage groups were reconstructed. Survival analyses (overall and cancer-specific) were conducted according to 6th and 8th editions through Kaplan-Meier analysis. Cox-regression multivariate model was also utilized for pair wise comparisons between different prognostic groups for overall and cancer-specific survival.
RESULTS: A total of 5382 patients with MPM were identified in the period from 2004 to 2013. According to the 6th edition, significant pair wise P values for overall survival included: IA vs. III (P=0.027); IA vs. IV: P<0.0001; IB vs. IV: P<0.0001; II vs. III: P<0.0001; II vs. IV: P<0.0001; III vs. IV: P<0.0001). According to the 8th edition, significant pair wise P values for overall survival included: all stages vs. IV: P<0.0001; IA vs. II: P=0.046; IA vs. IIIA: P=0.022; IA vs. IIIB: P <0.0001; IB vs. II: P<0.0001; IB vs. IIIB: P<0.0001; II vs. IIIA: P<0.0001; IIIA vs. IIIB: P<0.0001). C-index for 6th edition was 0.539 (SE: 0.008; 95% CI: 0.524-0.555); while C-index for 8th edition was 0.540 (SE: 0.008; 95% CI: 0.525-0.556). Based on the above findings, a simplified staging system was proposed and overall and cancer-specific survivals were evaluated according to the simplified system. For overall and cancer-specific survival assessment, P values for all pair wise comparisons among different stages were significant (<0.01).
CONCLUSION: The prognostic performance of both the 6th and 8th AJCC editions is unsatisfactory; there is a need for a more practical and prognostically relevant staging system for MPM.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AJCC; MPM; Mesothelioma; Prognosis; SEER

Mesh:

Year:  2017        PMID: 29110839     DOI: 10.1016/j.lungcan.2017.09.015

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  5 in total

Review 1.  Radical multimodality therapy for malignant pleural mesothelioma.

Authors:  Omar Abdel-Rahman; Zeinab Elsayed; Hadeer Mohamed; Mostafa Eltobgy
Journal:  Cochrane Database Syst Rev       Date:  2018-01-08

2.  Staging in the era of international databases: documented improvements with remaining challenges.

Authors:  Robert B Cameron
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

3.  Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma.

Authors:  Jeronimo Rafael Rodríguez-Cid; Orlando García-Acevedo; Javier Benjamin-Contreras; Diana Bonilla-Molina; Rodrigo Rafael Flores-Mariñelarena; Luis Martínez-Barrera; Jorge Arturo Alatorre-Alexander; Carla Paola Sanchez-Ríos; Maria Del Rosario Flores-Soto; Patricio Javier Santillan-Doherty; Erika Sagrario Peña-Mirabal
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

4.  Effect of lymphadenectomy on the prognosis for N0 gallbladder carcinoma patients: A study based on SEER database.

Authors:  Bin Wu; Yiyu Shen; Xujian Chen; Xiaoguang Wang; Zhengxiang Zhong
Journal:  Cancer Med       Date:  2021-09-14       Impact factor: 4.452

5.  The clinical prognostic factors of patients with stage IB lung adenocarcinoma.

Authors:  Qihai Sui; Jiaqi Liang; Zhengyang Hu; Xinming Xu; Zhencong Chen; Yiwei Huang; Mengnan Zhao; Cheng Zhan; Lin Wang; Zongwu Lin; Qun Wang
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.